A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

ClinicalTrials.gov ID: NCT05828511

Public ClinicalTrials.gov record NCT05828511. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 9, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1/2 Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients With Symptomatic Multiple Myeloma

Study identification

NCT ID: NCT05828511
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Regeneron Pharmaceuticals; Industry
Enrollment: 149 participants

Conditions and interventions

Conditions

Multiple Myeloma

Interventions

Linvoseltamab Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 18, 2023
Primary completion: Nov 1, 2035
Completion: Nov 1, 2035
Last update posted: Mar 18, 2026

2023 – 2035

United States locations

U.S. sites: 13
U.S. states: 8
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of California Los Angeles (UCLA)	Los Angeles	California	90095	Recruiting
UC Irvine Health	Orange	California	92868	Recruiting
Colorado Blood Cancer Institute/SCRI	Denver	Colorado	80218	Recruiting
Norton Cancer Institute	Louisville	Kentucky	40207	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08901	Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island	Mineola	New York	11501	Recruiting
Perlmutter Cancer Center	New York	New York	10016	Recruiting
Columbia University _ New York Presbyterian	New York	New York	10032	Recruiting
Stony Brook University Hospital	Stony Brook	New York	11794	Recruiting
Levine Cancer Institute	Charlotte	North Carolina	28204	Recruiting
Duke University Health System (DUHS)	Durham	North Carolina	27705	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05828511, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 18, 2026 · Synced May 9, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05828511 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →